Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is a major public health problem afflicting approximately one billion individuals worldwide. Liver biopsy is considered the gold standard for assessment of liver disease severity in patients with NAFLD. It is invasive and is associated with adverse effects, and also has higher inter-observer variability. Liver biopsy is impractical because of large number of individuals who have NAFLD and is not appropriate for screening. Therefore, non-invasive biomarkers to assess disease severity in NAFLD are needed. We use a combined approach of non-invasive imaging modalities and clinical, biochemical, metabolic and lipid biomarkers to grade liver fat and liver fibrosis, to assess presence of NAFLD, and to detect the progressive form of NAFLD, termed non-alcoholic steatohepatitis.
Methods: We evaluated 60 patients with presence of metabolic syndrome and suspected NAFLD. Other liver diseases, alcohol consumption ≥ 20 g/day, and use of drugs associated with liver steatosis were excluded. Anthropometric variables (weight, BMI, waist circumference), liver function tests, full blood count, serum lipids, fasting glucose, abdominal ultrasonography, liver transient elastography (TE) with fibroscan M probe (XL probe only in 5%) and CAP (controlled attenuation parameter) were assessed. The cut-off values for CAP and TE were defined as previously published. Indirect markers for fibrosis and steatosis were calculated.
Results: The mean age was 59 years, 59% female. 72% patients had diagnosis of diabetes mellitus (DM). The median weight was 90.3 kg, median BMI 32 kg/m² and median waist circumference – 112.8 cm. According to the Hepatic Steatosis Index, 4% of the patients were without NAFLD (HSI below 30) and 92% showed HSI higher than 36. Abdominal ultrasonography findings of hepatic steatosis were: 6% with no evidence of steatosis, 15% with grade I, 26% with grade II, and 53 % with grade III. The share of patients with CAP value under 215 db/m was 6% (suggestive steatosis under 33%), with CAP value between 217 db/m and 252 db/m – 10% (steatosis 34%-66%), with CAP value between 253 db/m and 296 db/m – 25% (steatosis over 67%), and 58% of patients had CAP value over 297 db/m. A FIB-4 index below 1.3 was found in 70% of patients. Respectively, 22% had FIB-4 index between 1.3 and 2.67. The share of patients with significant fibrosis with higher FIB-4 was 7.5%. TE values ≥ 7.9 kPa were identified in 34% of patients.
Conclusion: A combined approach of non-invasive biomarkers is better recommended for the diagnosis and grading of liver steatosis and for the detection of progressive forms of NAFLD.
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, Journal of Hepatology 2016, vol.64;
The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases, HEPATOLOGY, VOL. 67, NO. 1, 2018
Stefano Bellentani, MD, PhD; Gioconda Saccoccio, MD; Flora Masutti, MD; Lory S. Crocè, MD; Giovanni Brandi, at al, Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy, Annals of Internal Medicine, 18 January 2000 Vol: 132, Issue 2
Vernon G1, Baranova A, Younossi ZM; Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults, Aliment Pharmacol Ther, august 2011
Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, at al; Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes, Hepatology, Volume48, Issue3, September 2008
Nathalie C. Leite Gil F. Salles Antonio L. E. Araujo Cristiane A. Villela‐Nogueira Claudia R. L. Cardoso; Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus; Liver International, december 2008
Barbara Fruci, Stefania Giuliano, Angela Mazza, Roberta Malaguarnera, and Antonino Belfiore, Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment; Int J Mol Sci. 2013 Nov;
Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G.; Fatty infiltration of liver in hyperlipidemic patients.; Digestive diseases and sciences, 2000 Oct
Koehler EM1, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH at al. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study Journal of Hepatology, December 2012
Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology; 2002;
de Lédinghen V1, Vergniol J, Foucher J, Merrouche W, le Bail B., Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography., Liver international, 2012;
De Ledinghen V, Wong GL, Vergniol J, Chan HL, Hiriart JB, Chan AW, et al. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016;
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015
Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 1.
Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;
Tapper EB, Challies T, Nasser I, Afdhal NH, Lai M. The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2016
R.Loomba, Role of imaging-based biomarkers in NAFLD: Racant advances in clinical application and future research directions, J of Hepatology, 2018, vol 68
Eduardo Vilar-Gomez, Naga Chalasani, Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers, J of Hepatology, 2018, vol 68
